Myositis ossificans and fibro-osseous pseudotumor of digits, previously considered separate but similar tumors, are reclassified as being virtually identical neoplastic bone-forming tumors.[3]
Ischaemic fasciitis, previously termed atypical decubital fibroplasia or decubital ischemic fasciitis, was thought to be a non-neoplastic lesion and to occur only in the deep subcutaneous tissue at pressure points or bone prominences but more recently has been found to be a benign neoplasm that can occur in a wider range of tissue sites.[5][6]
Elastofibroma, also termed elastofibroma dorsi, were originally considered separate tumors with bone-forming capacity but are now considered as belonging to the same neoplastic spectrum [3]
Myofibrobastoma, also termed myofibroblastoma of soft tissues, is a mammary-type myofibroblastoma that occurs in non-mammary tissues[15] and may be as much as 10-fold more common than the mammary type.[14]
EWSR1-SMAD3-positive fibroblastic tumor, also termed EWSR1-SMAD3-rearranged fibroblastic tumor, is classified as an emerging (i.e. recently characterized[17]) entity by the World Health Organization, 2020.[18] It is a benign, small tumor located in the skin of the distal areas of the legs and, less commonly, the arm; it has occurred mostly in females. EWSR1-SMAD3-positive fibroblastic tumor was named based on the finding that its tumor cells express a EWSR1-SMAD3fusion gene. Since its initial description in 2018, a total of 15 cases have been reported as of 2021.[17][19]
Angiofibroma of soft tissue, also termed angiofibroma NOS (NOS indicates Not Otherwise Specified), an angiofibroma that develops in the extremities, particularly around or in the large joints.[21]
Lipofibromatosis, a mixture of lipofibromatosis tumors with different gene abnormalities;[27] these tumors differ from lipofibromatosis-like neural tumors which have not been classified as fibroblastic and myofibroblastic tumors.
Dermatofibrosarcoma protuberans, fibrosarcomatous, also termed fibrosarcomatous dermatofibrosarcoma protuberans (or fibrosarcomatous DFSP), is a more aggressive tumor than dermatofibrosarcoma protuberans tumors).[29]
Fibrosarcoma NOS, i.e. fibrosarcoma, not otherwise specified, or, alternatively, adult fibrosarcoma to distinguish it from rarely metastasizing infantile fibrosarcoma.[36][38]
^Slack JC, Bründler MA, Nohr E, McIntyre JB, Kurek KC (May 2021). "Molecular Alterations in Pediatric Fibroblastic/Myofibroblastic Tumors: An Appraisal of a Next Generation Sequencing Assay in a Retrospective Single Centre Study". Pediatric and Developmental Pathology. 24 (5): 405–421. doi:10.1177/10935266211015558. PMID33970051. S2CID234348021.
^ abHowitt BE, Fletcher CD (March 2016). "Mammary-type Myofibroblastoma: Clinicopathologic Characterization in a Series of 143 Cases". The American Journal of Surgical Pathology. 40 (3): 361–7. doi:10.1097/PAS.0000000000000540. PMID26523539. S2CID45911598.
^ abFoot O, Hallin M, Jones RL, Sumathi VP, Thway K (April 2021). "EWSR1-SMAD3-Positive Fibroblastic Tumor". International Journal of Surgical Pathology. 29 (2): 179–181. doi:10.1177/1066896920938124. PMID32615834. S2CID220326585.
^Habeeb O, Korty KE, Azzato EM, Astbury C, Farkas DH, Ko JS, Billings SD (February 2021). "EWSR1-SMAD3 rearranged fibroblastic tumor: Case series and review". Journal of Cutaneous Pathology. 48 (2): 255–262. doi:10.1111/cup.13870. PMID32901982. S2CID221572166.
^Coffin CM, Hornick JL, Zhou H, Fletcher CD (March 2007). "Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas". The American Journal of Surgical Pathology. 31 (3): 410–6. doi:10.1097/01.pas.0000213348.65014.0a. PMID17325483. S2CID25831659.
^Malik F, Santiago T, Newman S, McCarville B, Pappo AS, Clay MR (June 2020). "An addition to the evolving spectrum of lipofibromatosis and lipofibromatosis-like neural tumor: Molecular findings in an unusual phenotype aid in accurate classification". Pathology, Research and Practice. 216 (6): 152942. doi:10.1016/j.prp.2020.152942. PMID32299759. S2CID215803522.
^Casanova M, Brennan B, Alaggio R, Kelsey A, Orbach D, van Noesel MM, Corradini N, Minard-Colin V, Zanetti I, Bisogno G, Gallego S, Merks JH, De Salvo GL, Ferrari A (March 2020). "Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)". European Journal of Cancer. 127: 123–129. doi:10.1016/j.ejca.2019.12.021. PMID32007712. S2CID211012731.
^ abMohamed M, Fisher C, Thway K (June 2017). "Low-grade fibromyxoid sarcoma: Clinical, morphologic and genetic features". Annals of Diagnostic Pathology. 28: 60–67. doi:10.1016/j.anndiagpath.2017.04.001. PMID28648941.
^Wangsiricharoen S, Ali SZ, Wakely PE (2021). "Cytopathology of myxoinflammatory fibroblastic sarcoma: a series of eight cases and review of the literature". Journal of the American Society of Cytopathology. 10 (3): 310–320. doi:10.1016/j.jasc.2020.12.004. PMID33431307. S2CID231585966.
^Tivoli YA, Thomas JA, Chen AF, Weiss ET (November 2013). "Acral myxoinflammatory fibroblastic sarcoma successfully treated using Mohs micrographic surgery". Dermatologic Surgery. 39 (11): 1709–11. doi:10.1111/dsu.12308. PMID24118192. S2CID39916092.
^ abcMartínez-Trufero J, Cruz Jurado J, Gómez-Mateo MC, Bernabeu D, Floría LJ, Lavernia J, Sebio A, García Del Muro X, Álvarez R, Correa R, Hernández-León CN, Marquina G, Hindi N, Redondo A, Martínez V, Asencio JM, Mata C, Valverde Morales CM, Martin-Broto J (July 2021). "Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I". Cancer Treatment Reviews. 99: 102259. doi:10.1016/j.ctrv.2021.102259. ISSN0305-7372. PMID34311246.
^Hansen T, Katenkamp K, Brodhun M, Katenkamp D (August 2006). "Low-grade fibrosarcoma--report on 39 not otherwise specified cases and comparison with defined low-grade fibrosarcoma types". Histopathology. 49 (2): 152–60. doi:10.1111/j.1365-2559.2006.02480.x. PMID16879392. S2CID39305599.
^Clarke LE (October 2012). "Fibrous and fibrohistiocytic neoplasms: an update". Dermatologic Clinics. 30 (4): 643–56, vi. doi:10.1016/j.det.2012.06.005. PMID23021051.